MDVN
MDVN Articles
Friday's top analyst upgrades, downgrades and initiations include Chipotle Mexiican Grill, Cree, First Solar, NVIDIA, Seaworld, SunPower, Time and TJX Companies.
Published:
Last Updated:
In a new report, the RBC team focused on the companies that are making the most progress with treatments for patients with breast cancer.
Published:
Monday's top analyst upgrades, downgrades, and initiations include Aduro BioTech, Facebook, Lululemon, MGIC Investment, Nokia, Schlumberger and Yum! Brands.
Published:
One thing we have noticed as the market has crept steadily higher this year is that insider buying has never hit a wall.
Published:
Tuesday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include GE, Gilead Sciences, Oracle, Under Armour and El Pollo Loco.
Published:
A new Deutsche Bank report from the firm's quantitative strategies team highlights the current best buy ideas.
Published:
In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy right now.
Published:
These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. for Wednesday, September 24, 2014.
Published:
Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.
Published:
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
Published:
A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally from the hard sell-off. Here are the top large cap biotech stocks to buy at...
Published:
Last Updated:
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Published:
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of stocks that are rated...
Published:
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Published:
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
Published: